VitriVax: Funding, Investors & Team (Sep 2026)
VitriVax, a biotech startup based in Boulder, Colorado, specializes in creating a platform for vaccine formulation. The company has developed a unique technology, which was constructed at the University of Colorado with significant funding from NIH, NSF, the State of Colorado, and most recently, the Bill and Melinda Gates Foundation, totaling over $7.2M. This innovative technology aims to enhance the efficiency, affordability, and global accessibility of vaccines for both humans and animals.
VitriVax has raised $25.9M across 3 funding rounds on record, the most recent a Series B of $17.3M announced in Oct 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
VitriVax Company Profile and Key Stats
Latest funding round on record: Oct 2025.
VitriVax Funding Rounds
VitriVax raised $5.0M in an undisclosed round announced in Dec 2023.
1 years later, an undisclosed round of $3.6M was announced in Dec 2024.
10 months later, a Series B of $17.3M was announced in Oct 2025.
VitriVax Founders and Leadership Team
No contact details are on record for this team yet.
VitriVax Funding Compared to Other Biotechnology Startups
VitriVax's latest round of $17.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like VitriVax in Biotechnology and Boulder
Companies Similar to VitriVax
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
VitriVax Funding FAQs
What does VitriVax do?
VitriVax, a biotech startup based in Boulder, Colorado, specializes in creating a platform for vaccine formulation. The company has developed a unique technology, which was constructed at the University of Colorado with significant funding from NIH, NSF, the State of Colorado, and most recently, the Bill and Melinda Gates Foundation, totaling over $7.2M. This innovative technology aims to enhance the efficiency, affordability, and global accessibility of vaccines for both humans and animals.
How much funding has VitriVax raised?
VitriVax has raised $25.9M across 3 rounds on record. The most recent is a Series B of $17.3M announced in Oct 2025.
When did VitriVax last raise funding?
VitriVax's most recent funding round on record is a Series B of $17.3M, announced in Oct 2025.
Who founded VitriVax?
FundedIQ lists Bryan S (Founder), Robert Garcea (Founder) at VitriVax.
Where is VitriVax headquartered?
VitriVax is based in Boulder, Colorado, United States.
How many employees does VitriVax have?
VitriVax is in the 11-50 employee band.
How does VitriVax's funding compare to other Biotechnology startups?
VitriVax's latest round of $17.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's VitriVax Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for VitriVax is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.